MedTrace Logo

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-03-27

Study results available
· View outcomes & findings →

Summary

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

Teriparatide 40-mcg subcutaneous injection

DRUG

Denosumab Injection

One-time Denosumab injection

DRUG

Alendronate Oral Tablet

weekly alendronate for 8 weeks

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-04-30
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01750086 on ClinicalTrials.gov